Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML [Phase 1]
The Phase 1 trial of LAVA-051 in relapsed/refractory Chronic Lymphocytic Leukemia, Multiple Myeloma, or Acute Myeloid Leukemia has been term…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Observational study assessing venetoclax-based regimens for relapsed or refractory chronic lymphocytic leukemia in Italy, outside traditiona…
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma
This completed clinical trial update summarizes an assessment of financial difficulty experienced by participants with chronic lymphocytic l…
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) [Phase 2]
Phase 2 trial evaluating acalabrutinib in patients with chronic lymphocytic leukemia and mantle cell lymphoma after allogeneic stem cell tra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial evaluating frontline ibrutinib plus rituximab in unfit chronic lymphocytic leukemia has completed, assessing activity and sa…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: Real-world Study of Acalabrutinib
A real-world study of acalabrutinib sponsored by Ruijin Hospital is enrolling by invitation, investigating its use in mantle cell lymphoma a…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas [Phase 2]
A Phase 2 study evaluating the triple combination therapy DTRM-555 in relapsed/refractory chronic lymphocytic leukemia and relapsed/refracto…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. [Phase 1, Phase 2]
A Phase 1/2 open-label trial evaluating the safety and efficacy of concomitant administration of anti-CD19 CAR T-cell therapy and Lenalidomi…
-
CLINICAL_TRIALS trial_result · 2024-12-31Clinical Trial Update: FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia [Phase 3]
A Phase 3 trial comparing FCR (fludarabine, cyclophosphamide, rituximab) versus BR (bendamustine, rituximab) in patients with previously unt…
-
CLINICAL_TRIALS research · 2024-12-31Clinical Trial Update: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) [Phase 3]
A Phase 3 clinical trial compares three treatment strategies in previously untreated chronic lymphocytic leukemia: ibrutinib monotherapy, fi…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression [Phase 3]
A Phase 3 trial evaluating ibrutinib in previously untreated Binet stage A chronic lymphocytic leukemia at risk of progression has been comp…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL [Phase 2]
Phase 2 trial evaluating sequential bendamustine debulking followed by obinutuzumab, acalabrutinib, and venetoclax in relapsed/refractory ch…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation [Phase 3]
A Phase 3 trial in previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation compares standard chemoimmunotherapy …
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL [Phase 3]
Phase 3 study evaluating acalabrutinib (ACP-196) with venetoclax, with and without obinutuzumab (GA101), versus chemoimmunotherapy in previo…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
-
CLINICAL_TRIALS approval · 2024-12-18Clinical Trial Update: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
The document notes that pirtobrutinib is approved for marketing in relation to an expanded access program for multiple B-cell cancers, cover…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Personalized Multi-peptide Vaccination in CLL Patients [Phase 1]
This update notes the completion of a Phase 1 trial evaluating a personalized multi-peptide vaccination in patients with chronic lymphocytic…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Belimumab in Patients with Chronic Lymphocytic Leukemia [Phase 2]
Belimumab is being evaluated in a Phase 2 trial for relapsed chronic lymphocytic leukemia conducted by University Hospital Tuebingen; the st…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma [Phase 4]
Phase 4 clinical trial update: acalabrutinib in Indian patients with chronic lymphocytic leukemia and relapsed/refractory mantle cell lympho…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
Early-phase study evaluating the safety and preliminary efficacy of combining ibrutinib with pembrolizumab in chronic lymphocytic leukemia o…
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been term…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]
Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological maligna…